Tracking every rollback, reversal, and overreach — and the path back to the America we know.
Defense Secretary Pete Hegseth announced the Pentagon is ending mandatory flu vaccination requirements for active duty service members, citing medical autonomy and religious freedom. The policy change removes a long-standing health requirement for all U.S. military personnel, potentially affecting disease prevention protocols across the armed forces.
On January 28, 2025, President Trump signed Executive Order 14187 directing federal agencies to restrict gender-affirming medical treatments for minors under 18 years old. The order requires federal agencies to cease funding, authorization, or facilitation of puberty blockers, hormone therapy, and surgeries for transgender youth, and directs the Department of Health and Human Services to issue guidance restricting these treatments. Confirmed direct impact includes potential reduction in federal funding for medical facilities providing these treatments and changes to federal health program coverage policies affecting transgender minors seeking medical care.
On January 27, 2025, President Trump signed Executive Order 14184 directing the reinstatement of service members who were discharged under the military's COVID-19 vaccination mandate. The order requires the Department of Defense to reinstate affected service members and may provide back pay and benefits restoration. The confirmed direct impact includes restoring military status and pay for service members previously separated from the armed forces.
President Trump signed an executive order instructing the CDC to reduce the number of recommended childhood vaccines by approximately 50%. The order uses vague language referring to a health department assessment as a guide for federal immunization policy. The action directly threatens childhood disease prevention and herd immunity protections across the United States.
On January 24, 2025, President Trump signed Executive Order 14182 directing federal agencies to enforce the Hyde Amendment, which prohibits federal funds from being used to pay for abortion services except in cases of rape, incest, or danger to the mother's life. The order requires agencies to withhold federal funding from any organization that provides, refers for, or covers abortion services. The confirmed direct impact includes potential loss of federal funding for Planned Parenthood and other healthcare providers that offer abortion services alongside other medical care.
The Trump administration reversed its policy allowing federal funds for purchasing and distributing fentanyl detection strips used to test street drugs for contaminants. The Substance Abuse and Mental Health Services Administration issued guidance ending the practice as part of the administration's opposition to harm reduction initiatives. This change eliminates access to potentially life-saving drug testing resources for vulnerable populations.
Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana to a less-dangerous drug category under federal law. The change impacts federal regulation of marijuana in dozens of states that permit medical use, though it does not fully legalize marijuana federally. This significantly alters how the drug is regulated and enforced at the federal level.
The Federal Trade Commission and four states filed suit against the World Professional Association for Transgender Health, alleging deceptive claims about gender-affirming care for minors. The action targets medical professionals and organizations providing transgender healthcare services. This represents a coordinated federal and state effort to restrict access to gender-affirming medical care for transgender youth.
The Trump administration froze millions of dollars in federal funding for New York's Medicaid Fraud Control Unit (MFCU), which investigates and prosecutes healthcare provider fraud and patient abuse in Medicaid facilities. The action eliminates dedicated enforcement capacity for detecting fraud and protecting vulnerable patients in state Medicaid programs. New York loses federal resources for healthcare oversight and fraud prevention affecting thousands of Medicaid beneficiaries.
The FDA appointed Katherine Szarama as acting director of the Center for Biologics Evaluation and Research, replacing Vinay Prasad. This unit regulates vaccines and biological products for human use. The leadership change may impact vaccine approval processes and biological product oversight.